Search Results for: AIT Therapeutics Presented Data From
Articles
AIT Therapeutics Presented Data From Inhaled Nitric Oxide Study June 6, 2018
AIT Therapeutics, Inc. recently announced the results of its study titled Nitric Oxide Inhalations in CF Patients Infected with Mycobacterium Abscessus Complex: A Prospective, Open-Labeled Multi-Center Pilot Study at the 2018 American Thoracic Society (ATS) Conference in San Diego, CA.
Alladapt Immunotherapeutics Receives FDA Fast Track Designation for the Treatment of Mono- and Multi-Food Allergies November 22, 2023
Alladapt Immunotherapeutics, Inc. recently announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one...Summit Therapeutics Partners With Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody December 6, 2022
Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 Demonstrating Encouraging Safety & Efficacy Profile May 27, 2022
Purple Biotech Ltd. recently announced positive interim safety and efficacy data from the Phase 1 study of NT219 in adults with advanced solid tumors…..
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients With p53-Mutated Neoadjuvant Breast Cancer May 19, 2022
Aileron Therapeutics recently announced it has treated the first patients in its Phase 1b randomized, controlled clinical trial evaluating ALRN-6924...ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics November 3, 2021
Part 2 of this series fills in the story starting with the first oral HCV therapeutic, Vertex’s Incivek (telaprevir), which predated the first of the Gilead therapeutics by 2.5 years…
G1 Therapeutics & AstraZeneca Enter Clinical Trial Collaboration November 28, 2017
G1 Therapeutics, Inc. recently announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine...Mustang Bio Presents Clinical & Preclinical Data on MB-101 for Treatment of Glioblastoma November 29, 2016
Mustang Bio, Inc., a Fortress Biotech company, recently announced that Phase I clinical data and preclinical data on its MB-101...MARKET BRIEF - The Market for Type 2 Diabetes Therapeutics - Key Findings From a Recent Analysis of Global Drug Development Efforts November 19, 2013
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, summarizes key findings of Frost & Sullivan’s recent analysis of the type 2 diabetes therapeutics market, which examines in detail the insulin and non-insulin segments of this market on a global level.
THERAPEUTIC FOCUS - Perspectives on Sigma-2 Modulation as a Therapeutic Modality for Slowing Age-Related Degenerative Disease March 28, 2024
Anthony Caggiano, MD, PhD, believes there is evidence the sigma-2 receptor acts as a regulator of cellular processes, such as autophagy and protein trafficking, which are impaired in age-related degenerative diseases.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
Novartis AG Receives First Ever FDA Approval for CAR-T September 6, 2017
A new era in cancer treatment is now here. The US FDA recently gave the nod to Switzerland-based Novartis AG...HCV MARKET - Recent Success in HCV Treatment Brings Relief to Patients but Challenges to Companies November 7, 2016
INTRODUCTION Driven by several novel regimens recently receiving approval in the US and in Europe, high cure rates exceeding...11/14/2012 November 8, 2012
A Note to The Pharmaceutical Industry Upon The Re-Election of Barack Obama By: Matthew Herper, Forbes Staff, mherper@forbes.com I've covered...5/16/2012 May 14, 2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal...4/10/2012 April 8, 2012
Catalent & BASF Join Forces to Solve Bioavailabilty Challenges Catalent Pharma Solutions and BASF recently announced they have entered into...12/13/2011 December 11, 2011
Abbott Laboratories Spends $400 Million on Development Deal Abbott Laboratories and Reata Pharmaceuticals recently announced they have entered into a worldwide...11/29/2011 November 27, 2011
Biocon Launches Haselmeier's Insulin Pen in India Haselmeier recently announced that Biocon, one of Asia's premier biotechnology companies, has launched...
